Glass House Brands (GLAS) Free Cash Flow (2020 - 2026)
Glass House Brands' (GLAS) quarterly Free Cash Flow came in at -$8.2 million in Q1 2026, down 189.56% year-on-year from $9.2 million in Q1 2025, and up 67.28% on a QoQ basis from -$25.1 million in Q4 2025.
Glass House Brands (GLAS) Free Cash Flow (2020 - 2026) Analysis & Trends
Glass House Brands (GLAS) has 7 years of Free Cash Flow data on file, last reported at -$8.2 million in Q1 2026.
- On a quarterly basis, Free Cash Flow fell 189.56% year-over-year to -$8.2 million in Q1 2026; TTM through Mar 2026 was -$2.5 million, a 109.47% decrease from a year earlier, with the FY2025 full-year figure at $14.8 million, down 17.99% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$8.2 million, up from -$25.1 million in the prior quarter.
- Over the last five years, Free Cash Flow for GLAS reached as high as $21783.2 billion in Q3 2023 and fell as low as -$25.1 million in Q4 2025.
- Historically, Free Cash Flow has averaged $2191.9 billion across 5 years, with a median of $5.5 million in 2023.
- Across the five-year window, Free Cash Flow surged 207931285.36% in 2023 and sank 189.56% in 2026, its largest moves.
- Year by year, Free Cash Flow stood at $15478.4 billion in 2022, then slumped by 100.0% to -$4.6 million in 2023, then slumped by 113.75% to -$9.8 million in 2024, then slumped by 155.03% to -$25.1 million in 2025, then jumped by 67.28% to -$8.2 million in 2026.
- Per Business Quant data, the three most recent Free Cash Flow figures were -$8.2 million in Q1 2026, -$25.1 million in Q4 2025, and $3.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | -208.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 291.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -373.37 Mn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 363.70 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 348.40 Mn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 144.40 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -38.00 Mn |
| 10 | Glass House Brands | 873.84 Mn | 845.91 Mn | 10.02 Mn | -8.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.21 Mn |
| Mar 31, 2026 | -8.21 Mn |
| Dec 31, 2025 | -25.09 Mn |
| Dec 31, 2025 | -25.09 Mn |
| Sep 30, 2025 | 3.57 Mn |
| Sep 30, 2025 | 3.57 Mn |
| Jun 30, 2025 | 27.20 Mn |
| Jun 30, 2025 | 27.20 Mn |
| Mar 31, 2025 | 9.17 Mn |
| Mar 31, 2025 | 9.17 Mn |
| Dec 31, 2024 | -9.84 Mn |
| Dec 31, 2024 | -9.84 Mn |
| Sep 30, 2024 | 14.59 Mn |
| Sep 30, 2024 | 14.59 Mn |
| Jun 30, 2024 | 12.81 Mn |
| Jun 30, 2024 | 12.81 Mn |
| Mar 31, 2024 | 530,000.00 |
| Mar 31, 2024 | 530,000.00 |
| Dec 31, 2023 | -4.60 Mn |
| Dec 31, 2023 | -4.60 Mn |